1. Carfilzomib as salvage therapy in Waldenstrom macroglobulinemia: a case series. Issue 1 (2nd January 2018) Authors: Vesole, David H.; Richter, Joshua; Biran, Noa; McBride, Laura; Anand, Palka; Huang, Mei; Kumeli, Anita-Zahlten; Klippel, Zandra; Iskander, Karim; Siegel, David S. Journal: Leukemia & lymphoma Issue: Volume 59:Issue 1(2018) Page Start: 259 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Durability of complete response after blinatumomab therapy for relapsed/refractory diffuse large B-cell lymphoma. Issue 11 (18th September 2020) Authors: Viardot, Andreas; Hess, Georg; Bargou, Ralf C.; Morley, Nicholas J.; Gritti, Giuseppe; Goebeler, Maria-Elisabeth; Iskander, Karim; Cohan, David; Zhang, Alicia; Franklin, Janet; Coyle, Luke Journal: Leukemia & lymphoma Issue: Volume 61:Issue 11(2020) Page Start: 2767 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Efficacy and safety of carfilzomib-lenalidomide-dexamethasone in newly diagnosed multiple myeloma: pooled analysis of four single-arm studies. Issue 10 (24th August 2022) Authors: Landgren, Ola; Kazandjian, Dickran; Roussel, Murielle; Jasielec, Jagoda; Dytfeld, Dominik; Anderson, Aparna; Kervin, Tara A.; Iskander, Karim; McFadden, Ian; Jakubowiak, Andrzej J. Journal: Leukemia & lymphoma Issue: Volume 63:Issue 10(2022) Page Start: 2413 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Once‐weekly (70 mg/m2) vs twice‐weekly (56 mg/m2) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, A.R.R.O.W., and CHAMPION‐1 trials. (28th February 2020) Authors: Moreau, Philippe; Stewart, Keith A.; Dimopoulos, Meletios; Siegel, David; Facon, Thierry; Berenson, James; Raje, Noopur; Berdeja, Jesus G.; Orlowski, Robert Z.; Yang, Hui; Ma, Haijun; Klippel, Zandra; Zahlten‐Kumeli, Anita; Mezzi, Khalid; Iskander, Karim; Mateos, Maria‐Victoria Journal: Cancer medicine Issue: Volume 9:Number 9(2020) Page Start: 2989 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Real-world evidence for carfilzomib dosing intensity on overall survival and treatment progression in multiple myeloma patients. (July 2022) Authors: Raje, Noopur; Medhekar, Rohan; Panjabi, Sumeet; Hines, Dionne M; Wang, Xin; Iskander, Karim; Welliver, Tim; Wade, Rolin L; Ailawadhi, Sikander Journal: Journal of oncology pharmacy practice Issue: Volume 28:Number 5(2022) Page Start: 1130 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. The BiTE (bispecific T‐cell engager) platform: Development and future potential of a targeted immuno‐oncology therapy across tumor types. Issue 14 (13th May 2020) Authors: Einsele, Hermann; Borghaei, Hossein; Orlowski, Robert Z.; Subklewe, Marion; Roboz, Gail J.; Zugmaier, Gerhard; Kufer, Peter; Iskander, Karim; Kantarjian, Hagop M. Journal: Cancer Issue: Volume 126:Issue 14(2020) Page Start: 3192 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗